Antiviral ensitrelvir cuts risk of COVID-19 in household contacts by two-thirds, study finds
medicalxpress - The antiviral drug ensitrelvir prevents infection in household contacts of COVID-19 patients when given within 72 hours after symptom onset in the index patient, according to a Phase III randomized controlled trial published in the New England Journal of …
AI Summary: A randomized trial shows the oral antiviral ensitrelvir, used as post‑exposure prophylaxis, reduced the risk of symptomatic COVID‑19 in household contacts by roughly two‑thirds. The finding suggests a practical option for preventing spread after close exposure, offering public‑health teams a less dramatic but highly useful tool than lockdowns.
Related Stories
Engineered 15‑strain biotherapeutic matches donor FMT for C. difficile / 5 wks
One hepatitis B drug shows early functional cures in trial / 6 wks
Study finds MenB vaccine does not prevent gonorrhea in men / 11 hrs
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 2 months
First‑in‑human CRISPR/Cas12a sickle cell therapy treated; gene editing shows promise / 3 months
Denali drug receives accelerated approval for rare CNS indication / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Food Safety, Healthcare, Mergers and Acquisitions, Olfaction and look for the RSS link.
StackHealth Time Machine